Combining inotuzumab ozogamicin with the p38 inhibitor BIRB 796 and venetoclax exerts synergistic cytotoxicity in B-cell precursor acute lymphoblastic leukemia including very high risk t(17;19) acute lymphoblastic leukemia
To improve mechanism-based pharmacotherapy for B-cell precursor acute lymphoblastic leukemia (BCP-ALL), we analyzed mode of action and potential synergies of inotuzumab ozogamicin (INO) with the p38 kinase inhibitor BIRB 796 and the BCL2-specific BH3 mimetic venetoclax (VEN) in BCP-ALL cell lines a...
Збережено в:
| Автори: | , , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
Ferrata Storti Foundation
2026-06-01
|
| Серія: | Haematologica |
| Онлайн доступ: | https://haematologica.org/article/view/14257 |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|